Low-dose Atropine for the Prevention of Myopia Progression in Danish Children

Summary

Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated with a risk of potentially blinding complications such as retinal detachment and myopic maculopathy. There is a direct association between the degree of myopia and the risk of complications. Myopia develops in childhood and during adolescence. To prevent higher degrees of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine eye drops have been shown to reduce myopia progression by 50% in Asian populations but its effect in non-Asian populations is unknown. The aim of this study is to investigate if low-dose atropine can reduce myopia progression in Danish children and teenagers. The study is an investigator initiated randomized clinical trial conducted as a collaboration between three Danish Eye Departments covering all of Denmark.

Timeline

Start

2019-05-30

Primary completion

2024-04-23

Completion

2024-04-23

Publications

• Hansen NC, Behrens CM, Hvid-Hansen A, Hamann S, Kessel L. Peripapillary hyperreflective ovoid mass-like structure (PHOMS): prevalence, risk factors, and development over time in Danish myopic children. J AAPOS. 2024 Dec;28(6):104034. doi: 10.1016/j.jaapos.2024.104034. Epub 2024 Nov 8.
• Hansen NC, Hvid-Hansen A, Bek T, Moller F, Jacobsen N, Kessel L. The Macular Choroidal Thickness in Danish Children with Myopia After Two-Year Low-Dose Atropine and One-Year Wash-Out: A Placebo-Controlled, Randomized Clinical Trial. Ophthalmol Ther. 2024 Dec;13(12):3111-3122. doi: 10.1007/s40123-024-01051-5. Epub 2024 Oct 18.
• Hansen NC, Hvid-Hansen A, Moller F, Bek T, Larsen DA, Jacobsen N, Kessel L. Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety. BMC Ophthalmol. 2023 Oct 30;23(1):438. doi: 10.1186/s12886-023-03177-9.

Drugs

Indications